Cardiovascular disease is a leading cause of death among liver transplant (LT) recipients. With a rising burden of posttransplantation metabolic disease, increases in cardiovascular-related morbidity and mortality may reduce life expectancy after LT. It is unknown if the risk of long-term major cardiovascular events (MCEs) differs among LT recipients with varying diabetic states. We performed a retrospective cohort study of LT recipients from 2003 through 2013 to compare the incidence of MCEs among patients (1) without diabetes, (2) with pretransplantation diabetes, (3) with de novo transient posttransplantation diabetes, and (4) with de novo sustained posttransplantation diabetes. We analyzed 994 eligible patients (39% without diabetes, 24% with pretransplantation diabetes, 16% with transient posttransplantation diabetes, and 20% with sustained posttransplantation diabetes). Median follow-up was 54.7 months. Overall, 12% of patients experienced a MCE. After adjustment for demographic and clinical variables, sustained posttransplantation diabetes was the only state associated with a significantly increased risk of MCEs (subdistribution hazard ratio 1.95, 95% confidence interval 1.20-3.18). Patients with sustained posttransplantation diabetes mellitus had a 13% and 27% cumulative incidence of MCEs at 5 and 10 years, respectively. While pretransplantation diabetes has traditionally been associated with cardiovascular disease, the long-term risk of MCEs is greatest in LT recipients with sustained posttransplantation diabetes mellitus.
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Introduction
Through advances in surgical techniques, organ donation, critical care, and immunosuppression, liver transplant (LT) recipients in the United States have expected 1-and 5-year survival rates of greater than 90% and 70%, respectively (1) . During the past decade, however, there has been a plateau in long-term graft attrition and patient survival rates (2, 3) . This plateau parallels a rise in the prevalence of posttransplantation metabolic syndrome and cardiovascular disease (CVD), which is now a leading cause of non-graft-related death of LT recipients (4) (5) (6) . With increasing rates of posttransplantation metabolic syndrome, an aging population of transplant recipients, and widespread use of calcineurin inhibitors for the prevention of graft rejection, LT recipients have 2.6 times greater risk of death from CVD compared with an ageand sex-matched non-transplant recipient population (4, 7) . Furthermore, as the proportion of patients undergoing LT for nonalcoholic fatty liver disease (NAFLD) rises, the contribution of CVD to all-cause mortality of LT recipients is anticipated to increase during the next 20 years (5).
During the past decade, de novo posttransplantation diabetes mellitus (PTDM), encompassing both transient and sustained forms of PTDM, has been increasingly recognized as a complication of solid organ transplantation (8, 9) . Risk factors for PTDM include older age at transplantation, male gender, African American race/ethnicity, Hispanic ethnicity, chronic hepatitis C virus infection, NAFLD, tacrolimus use, weight gain after LT, and acute graft rejection (ACR) (4, (8) (9) (10) . Diabetes mellitus (DM) in the posttransplantation setting has previously been identified as an independent predictor of mortality, diminished graft survival, and posttransplantation cardiovascular events (11) (12) (13) . However, many prior investigations of the prognostic impact of PTDM and risk factors for post-LT CVD did not distinguish de novo PTDM from pre-LT DM persisting after LT or further subdivide PTDM into transient and sustained forms (12) (13) (14) (15) . Furthermore, cardiovascular events, such as arrhythmia and congestive heart failure, have often been incorporated in composite outcomes of cardiovascular events, preventing study of the relationship of DM with ischemic events specifically.
Thus, the differential associations between specifically defined diabetic states and ischemic post-LT cardiac events have not been previously investigated in a large cohort of LT recipients. In this study, we linked Organ Procurement and Transplantation Network (OPTN)/United Network for Organ Sharing (UNOS) data with data from a large single-center LT cohort to (1) compare the risk of long-term MCEs among LT recipients with varying diabetic states and (2) determine the impact of MCEs on mortality after LT. We hypothesized that patients with sustained PTDM (s-PTDM) have a significantly greater risk of MCE than do patients without diabetes mellitus (DM) and that MCEs are associated with post-LT mortality.
Methods

Data source
This retrospective cohort study used data from the Penn Data Store (PDS) and the OPTN/UNOS data set. PDS is a clinical data repository maintained within the University of Pennsylvania Health System (UPHS) Data Analytic Center, which supplies clinical, administrative, and pharmacy data through an automated extraction of data elements from multiple patient record systems within the health network. The OPTN/UNOS data set includes donor and recipient transplant-related data. This study used data obtained from the PDS and OPTN/UNOS from all patients who underwent LT at the Hospital of the University of Pennsylvania (HUP) from January 1, 2003, through December 31, 2013. These dates were chosen to maximize acquisition of electronic administrative, laboratory, and pharmacy data from the PDS and to ensure at least 18 months of follow-up for the last included LT recipient in the cohort.
Study subjects
We assembled a single-center cohort of adult (>18 years of age) LT recipients from January 1, 2003, through December 31, 2013. We excluded LT recipients with less than 6 months of post-LT follow-up due to the inability to adequately assess their posttransplantation DM status. Multiorgan recipients and patients with a solid organ or hematopoietic stem cell transplant before the date of LT were excluded due to their propensity to receive immunosuppressive regimens that differ from the standard regimen used in LT recipients at our institution, as more-intensive immunosuppressive regimens and prolonged glucocorticoid exposure may confer an increased risk of PTDM. Patients with a history of MCEs before cohort entry were excluded. Finally, LT recipients listed as status 1A were excluded as their risk of post-LT metabolic disease and CVD may differ from those transplanted for chronic liver disease.
Follow-up period
Patients entered the cohort 6 months from the date of LT. This was selected as the cohort entry time to reduce DM exposure misclassification and to eliminate immortal time bias associated with ascertaining DM exposure in the first 6 months after LT. Patients were censored from the analysis on the date of their last inpatient or outpatient counter or on the study end date, September 30, 2015 , the last date of use for the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM).
Diabetic states and covariates
Ascertainment of DM status was achieved via manual chart review in conjunction with extracted PDS diagnosis codes from inpatient and outpatient encounters as well as laboratory and pharmacy data. DM was diagnosed according to the American Diabetes Association definition (hemoglobin A1c >6.5%, fasting plasma glucose ≥126 mg/dL, a 2-h plasma glucose level of ≥200 mg/dL or higher during a 75-g oral glucose tolerance test, a random plasma glucose of 200 mg/dL or higher on two occasions, or requiring medication for the management of hyperglycemia) (16) . By using this diagnostic criteria for DM, patients were divided into four DM groups: (1) normal-patients lacking a diagnosis of DM both before and after LT, (2) pre-LT DM-patients with a diagnosis of DM before the date of LT, (3) transient-PTDM (t-PTDM)-patients with de novo DM for >30 days but remitting sooner than 6 months from the date of LT, and (4) s-PTDM-patients with de novo DM for at least 6 months after LT. For patients in which s-PTDM was diagnosed >6 months after LT, patients were categorized as "normal" until they met criteria for the diagnosis of DM.
Covariate selection was based on partial knowledge of the underlying causal structure associating post-LT metabolic disease with MCEs. In addition, we a priori selected covariates associated with DM, MCEs, or potential confounders of the association between DM and MCE to be included in the final multivariable regression model (17) . Collected covariates included patient demographics (sex, age at LT, race/ethnicity, body mass index [BMI] at LT, change in BMI after LT, pack-years of cigarettes smoked at time of LT), LT-related variables (cause of liver disease, MELD at LT, deceased vs. living donor, hepatocellular carcinoma [HCC] on explant, year of LT), biopsy proven ACR, diagnosis of hypertension or hyperlipidemia, presence or development of ESRD, and prescription of statin (both time varying). Change in BMI was defined as the difference between the last recorded post-LT BMI measurement before cohort entry and the BMI at LT.
Study outcomes
The primary outcome was MCE, defined as a composite of cardiac arrest, fatal and nonfatal myocardial infarction, ischemic stroke, and symptomatic peripheral artery disease requiring a revascularization intervention. Ascertainment of each MCE event was achieved through an automated query of PDS data to identify one inpatient or two outpatient encounters with an ICD-9-CM diagnosis code and/or ICD-9-CM procedure codes with high positive predictive value for cardiac arrest, myocardial infarction, ischemic stroke, and symptomatic peripheral vascular disease requiring intervention (see Table S1 ) (18) (19) (20) (21) (22) . All MCEs identified through the automated query were adjudicated via manual chart review by the primary author (G.R.). Further, a random sample of 15% of patients without a MCE underwent manual chart review to determine the negative predictive value of the algorithm. The secondary outcome was death. Death was determined through an automated query of PDS data for date deceased, manual chart review, and linkage to UNOS/OPTN data.
Statistical analyses
Baseline clinical and demographic characteristics were summarized by the use of median and interquartile range (IQR) values for continuous variables or count (percent) for categorical variables. Comparisons among the DM groups were performed by using v 2 and Kruskal-Wallis tests, when appropriate. The Cuzick nonparametric test for trend across ordered groups was used to test for temporal changes in age at LT, BMI at LT, and MELD score over time (23) . Univariable and multivariable logistic regression models were used to determine demographic and clinical factors associated with the development of t-PTDM and s-PTDM among patients without pre-LT DM. Variables with a p value of <0.20 were included in a multivariable model to test for independent associations with t-PTDM and s-PTDM.
Multivariable competing risk Cox regression models, according to the methods of Fine and Gray (24, 25) , were used to compare MCE risk among patients by their time-varying diabetic state. MCE was the primary outcome, and death was the competing event. Death was modeled as a competing risk because if the mortality rate in one DM exposure group was substantially higher, the calculated risk of MCE may be biased without accounting for death being a competing risk (25, 26) . In the multivariable model, we adjusted for a priori selected demographic and clinical characteristics associated with MCEs or death that were available in our data set: age at LT, gender, race, etiology of liver disease, pack-years of cigarettes smoked, hypertension, and hyperlipidemia. In addition, all other covariates were fit in a univariable model, and those with a p value <0.10 were tested for inclusion in the multivariable model by using a change-in-effect criterion. Covariates that resulted in a >10% change of the b-coefficient of at least one DM status after inclusion into the univariable model were considered confounders and added to the final multivariable model (27, 28) . The adjusted cumulative incidence of MCEs was calculated for each DM group. Using the Wald test, we tested for a priori interactions between DM status and BMI at LT, DM status and change in BMI, and DM and hyperlipidemia, given that the association between DM status and MCE may be differentially impacted by obesity and the presence of hyperlipidemia, two components of the metabolic syndrome.
Univariable and multivariable models were fit by both using complete case analysis and following multiple imputation for missing data (BMI at LT 12.7% missing, change in BMI 23.6% missing, MELD 18.6% missing, and pack-years 26.5% missing) through the chained equations approach. Thirty imputed sets were created by using the predictive mean matching method (29, 30) stratified by year of LT. This semiparametric matching method uses only observed values to generate a linear prediction model, such that the distribution and range of the data are preserved and plausible imputed values are guaranteed (31) .
In the secondary analysis, we compared time to death of LT recipients who experienced an MCE with those who remained MCE free. MCE was treated as a time-varying covariate. Univariable Cox proportional hazards models were fit to identify covariates associated with mortality. A multivariable Cox proportional hazards model incorporating all covariates from the multivariable model of the primary analysis was fit to compare adjusted survival among patients before and after MCE. By using the Wald test, we tested for an interaction between MCE and DM status, given that the association between MCE and death may be differentially affected by PTDM. We tested Schoenfeld residuals to determine if the proportional hazards assumption was upheld for the two groups.
Two-sided p values <0.05 were considered statistically significant. Analyses were performed by using STATA statistical software, version 14.0 (StataCorp, College Station, TX). The institutional review board at the University of Pennsylvania approved this study. Table S2 ). In contrast, African American race (OR 1.66, 95% CI 1.06-2.58), hepatitis C (OR 1.46, 95% CI 1.00-2.12), NASH (OR 2.14, 95% CI 1.10-4.16), MELD score (OR 1.02, 95% CI 1.00-1.04), ACR (OR 2.08, 95% CI 1.10-3.93), and year of LT (OR 0.91, 95% CI 0.87-0.96) were independently associated with the development of s-PTDM (Table S3) .
Results
Cohort characteristics
MCE risk
Overall, 119 (12%) patients experienced a MCE-10 patients had cardiac arrest, 53 experienced a myocardial infarction, 35 had an ischemic stroke, and 21 patients required intervention for symptomatic peripheral artery disease. A random selection of 131 patients without an identified MCE were subject to manual chart review; two patients had experienced a MCE (one myocardial infarction and one ischemic stroke) and were treated at hospitals outside our health system. The positive and negative predictive values of the automated algorithm to identify MCE were 99.1% and 98.4%, respectively.
Among patients who experienced a MCE, the median time to MCE was 39.4 months after LT (IQR 17.0-71.3 months). Patients with s-PTDM had the highest incidence of MCE (18.7%), while those with t-PTDM had the lowest (5.5%) (Figure 1 ). The incidence of MCE in normal patients and those with pre-LT DM, t-PTDM, and s-PTDM was 14.3, 23.0, 11.5, and 44.4 per 1000 personyears, respectively. In univariable competing risk regression analyses, DM status, race/ethnicity, age at LT, etiology of liver disease, pack-years smoked, hypertension, hyperlipidemia, statin use, end-stage renal disease diagnosis, and year of LT were significantly associated with MCEs (Table 2) . Interactions between DM status and BMI, DM status and change in BMI, and DM status and hyperlipidemia were not significant (p = 0.48, p = 0.35, and p = 0.76, respectively). After we tested for confounding of the association between DM status and MCE, year of LT resulted in a >10% change in the b-coefficients of DM status and was added to the final multivariable model in addition to the variables selected a priori.
In multivariable competing risk regression (Table 3) , s-PTDM was the only DM status that was significantly associated with MCE (subdistribution hazard ratio [SHR] 1.95, 95% CI 1.20-3.18). The risk of MCE was greater in patients with s-PTDM than those with pre-LT DM (SHR 1.81, 95% CI 1.14-2.90) and those with t-PTDM (SHR 2.52, 95% CI 1.22-5.23). Age at LT (SHR 1.04, 95% CI 1.02-1.07), hypertension (SHR 1.53, 95% CI 1.03-2.28), and hyperlipidemia (SHR 2.27, 95% CI 1.48-3.47) were also significantly associated with MCE. Pack-years of cigarettes smoked had a nonsignificant association with MCEs (SHR 1.01, 95% CI 1.00-1.02). Analyses using complete case analysis were similar to those using imputation for missing covariates (results not shown). The 60-and 120-month cumulative incidence of MCE in patients with s-PTDM was 13% and 27% compared with 9% and 19% in those with pre-LT DM, respectively (Figure 2 ).
MCEs and overall mortality
During study follow-up, 274 (27%) patients died, with an incidence rate of 4.6 deaths per 1000 person-years. Of the 274 deaths, 42 (15%) occurred following a MCE, with a median time to death after MCE of 0.20 month (95% CI 0.1-14.8 months). Sixteen (38%) of 42 deaths were attributed to cardiovascular disease. Cardiovascularrelated mortality occurred in one (0.4%) of 232 patients who died without ever experiencing an MCE (congestive heart failure). The incidence rate of death in patients who (Table S4) were significantly associated with risk of death. After multivariable Cox regression, an MCE was associated with a greater than threefold increased risk of death (HR 3.54, 95% CI 2.22-5.63) (Figure 3 ). DM status did not result in significant effect modification of the association between MCE and death (p = 0.17). Pre-LT DM, s-PTDM, hepatitis C virus infection, and year of LT were significantly associated with death in the multivariable model (Table S4) . These results were similar to those of the multivariable model using complete case analysis. The test of Schoenfeld residuals indicates that the assumption of proportional hazards was not violated (p = 0.23).
Discussion
In this cohort study, we compared the incidence of first MCE among LT recipients transplanted with pre-LT DM, t-PTDM, s-PTDM, or lack of DM, accounting for all-cause mortality as a competing risk. We observed that s-PTDM was the only diabetic state associated with an increased risk of MCE. In addition, the cumulative incidence of MCE in patients with s-PTDM surpassed that of patients with pre-LT DM throughout follow-up. Furthermore, patients who experienced MCE had a greater than threefold increased risk of death, confirming the significant negative impact of MCEs on survival after LT.
As demonstrated in our cohort, PTDM is a common complication after solid organ transplantation. Our findings confirm earlier data suggesting that s-PTDM and pre-LT DM are associated with diminished overall post-LT survival (11) . However, prior associations between (10) 25 (6) 53 (22) 8 (5) 17 (9) Autoimmune/ cholestatic 116 (12) 50 (13) 18 (7) 26 (16) 22 (11) Hepatitis B virus and other 87 (9) 35 (9) 17 (7) 20 (12) 15 (8) MELD score (median, IQR) (14) 33 (8) 64 (26) 14 (9) 29 ( (14) 46 (12) 40 (17) 18 (11) 34 ( PTDM and post-LT CVD have been inconsistent. John et al compared transplant outcomes of 46 LT recipients with PTDM with those of 92 controls without PTDM (14) . PTDM patients had a greater incidence of cardiac complications. However, hypertension composed the majority of cardiac complications in both patients with PTDM (18 of 26 reported cardiac events) and controls (20 of 24 reported cardiac events). In a more recent study, Kuo et al reported that pre-LT DM, but not PTDM, was associated with cardiovascular mortality (15) . The comparative risk of MCEs was not reported. In this study, DM exposure was characterized based on data from the UNOS/OPTN database, and s-PTDM could not be distinguished from t-PTDM. As a result, it is likely that the diagnosis of PTDM is less accurately recorded than pre-LT DM in UNOS/OPTN and therefore susceptible to misclassification bias, which would be expected to obscure an association between PTDM and cardiovascular mortality. Variables selected a priori for inclusion in the final multivariable model. This study has several strengths. First, we had long-term follow-up of nearly 1000 LT recipients. Second, the use of automated data extraction techniques from the health system data warehouse allowed use of granular data elements including inpatient and outpatient encounter diagnoses, procedures codes, laboratory results, and medications prescribed. This facilitated a rigorous characterization of patient DM status according to the standard definition of the World Health Organization/American Diabetes Association, reducing the risk of misclassification that commonly occurs when using OPTN/UNOS data and allowing for the discrimination of t-PTDM and s-PTDM. Third, all MCEs identified by the automated algorithm were adjudicated by manual chart review, allowing for performance assessment of this automated algorithm in this patient cohort. We confirmed high sensitivity and specificity of the outcome definition. Finally, by using a competing risk model to estimate the comparative risk of MCEs, we minimized potential bias introduced by differential rates of death among patients of differing DM exposures (25, 26) .
The results presented should be interpreted with several limitations in mind. As noted previously, the rate of MCEs among patients with pre-LT DM may be lower than that of patients with s-PTDM due to the screening and selection processes for LT that excludes those with underlying CVD from transplant candidacy. While this could be considered a form of selection bias, it does not lessen the importance of the findings that patients with s-PTDM have increased risk of CV events relative to patients without DM. Second, some MCEs may have been missed, particularly if they occurred outside our health system and were not reported to our center. However, we expect the distribution of missed events is nondifferential across diabetic groups and, as a result, the reported effect estimate may be biased toward the null hypothesis. Most importantly, there is the possibility of unmeasured confounding related to immunosuppressive drugs. Glucocorticoids and calcineurin inhibitors, both used to prevent and treat graft rejection, are diabetogenic. Moreover, acute rejection has been shown to be associated with mortality (15, 33) . While adjusting for incident ACR may account for some differences in immunosuppression dosing, data from both the PDS and OPTN/UNOS lack consistent longitudinal patient data on immunosuppression medications. Nonetheless, we do not believe this biases our findings substantially because, being a single-center study, single organ LT recipients are treated with a relatively homogeneous immunosuppressive regimen-combination therapy with tacrolimus and prednisone immediately after LT followed by tapering and cessation of prednisone during the ensuring 3-to 6-month period. In addition, induction is not used at our center, and the decision to add a second immunosuppressive agent, such as mycophenolate mofetil or azathioprine, is individualized on the basis of renal function, prior graft rejection, and presence of immune-mediated liver disease. Finally, while there was a moderate amount of missing data for four covariates, the effect estimates obtained from multivariable regression models using multiple imputation did not differ significantly from those utilizing complete case analysis.
In summary, we have demonstrated that LT recipients with s-PTDM should be considered to be at the greatest risk of nonperioperative cardiovascular morbidity after liver transplantation. MCEs, including cardiac arrest, myocardial infarction, stroke, and ischemic peripheral vascular disease, are associated with a greater than threefold increased risk of death. These findings indicate that cardiovascular risk stratification and risk reduction strategies should not be restricted to the preoperative and early postoperative periods and should continue throughout the posttransplantation period, particularly in patients with acquired metabolic disease. As the prevalence of posttransplantation metabolic disease increases, novel risk stratification tools incorporating posttransplantation metabolic disease indicators, such as s-PTDM, are needed to predict the risk of CVD and to guide pharmacologic and behavioral prevention strategies.
Supporting Information
Additional Supporting Information may be found in the online version of this article. Table S1 : ICD-9-CM diagnostic and procedure codes for ascertainment of major cardiovascular events. 
